Stockscreener 앱 받기
0.235
1.26%
-0.003
Cellectar Biosciences Inc 주식(CLRB)의 최신 뉴스
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com - Defense World
Oppenheimer Downgrades Cellectar Biosciences (CLRB) - MSN
Roth Capital Has Optimistic Outlook of CLRB Q1 Earnings - Defense World
Cellectar Biosciences Implements Workforce Reduction Plan to Enhance Operational Efficiency - Defense World
Cellectar Biosciences (FRA:NV4) 10-Year Sharpe Ratio : -0.19 (As of Dec. 12, 2024) - GuruFocus.com
Cellectar Biosciences (FRA:NV4) 3-Year Sortino Ratio : -0.47 (As of Dec. 12, 2024) - GuruFocus.com
Cellectar Biosci stock hits 52-week low at $0.27 amid sharp decline - Investing.com
Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut - MarketWatch
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options - Benzinga
Cellectar Biosciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Cellectar stock plunges 50% post-market on restructuring news - MSN
Cellectar stock plunges 50% post-market on restructuring news (NASDAQ:CLRB) - Seeking Alpha
CLRBCellectar Biosciences INC NEW Latest Stock News & Market Updates - StockTitan
Cellectar refocuses on solid tumor radiotherapies - Investing.com
Cellectar Biosciences Provides Strategic Update on Clinical - GlobeNewswire
Cellectar Shifts Strategy After FDA Feedback, Cuts 60% Workforce to Advance Cancer Pipeline - StockTitan
Waldenstrom Macroglobulinemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AbbVie, Cellectar Biosciences, TG Therapeutics, Eli Lilly and Company, Celgene Corp - Barchart
Waldenstrom Macroglobulinemia Market Growth to Accelerate - openPR
Cellectar Biosci stock hits 52-week low at $1.38 By Investing.com - Investing.com Canada
Cellectar Biosci stock hits 52-week low at $1.38 - Investing.com
Ladenburg Thalmann resumed coverage on Cellectar Biosciences with a new price target - Quantisnow
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip? - AOL
Cellectar Biosciences (STU:NV4) Forward Dividend Yield % : 0.00% (As of Dec. 01, 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Volatility : 73.35% (As of Nov. 29, 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Total Stockholders Equity : €13.66 Mil (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) PE Ratio : At Loss (As of Nov. 28, 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Other Long Term Assets : €0.03 Mil (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Current Accrued Expense : €7.48 Mil (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Quick Ratio : 1.77 (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (FRA:NV4) 3-Year Book Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (FRA:NV4) Margin of Safety % (DCF FCF Based) : N/A (As of Nov. 26, 2024) - GuruFocus.com
CLRB (Cellectar Biosciences) EPS without NRI : $-2.17 (TTM As of Sep. 2024) - GuruFocus.com
12,500 Shares in Cellectar Biosciences, Inc. (NASDAQ:CLRB) Purchased by Oppenheimer & Co. Inc. - Defense World
Cellectar Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.com
Roth Capital Analysts Decrease Earnings Estimates for CLRB - Defense World
Oppenheimer Lowers Cellectar Biosciences (NASDAQ:CLRB) Price Target to $12.00 - Defense World
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2024 Earnings Call Transcript - Insider Monkey
Cellectar Signs Critical Radioisotope Supply Deal for Cancer Drug Development | CLRB Stock News - StockTitan
Roth Capital Has Bearish Forecast for CLRB FY2024 Earnings - MarketBeat
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides Corporate Update - Defense World
Equities Analysts Offer Predictions for CLRB Q1 Earnings - Defense World
What is Roth Capital's Estimate for CLRB Q1 Earnings? - MarketBeat
Oppenheimer cuts Cellectar Biosciences stock target, outperform on Q3 financials - Investing.com UK
Oppenheimer Has Lowered Expectations for Cellectar Biosciences (NASDAQ:CLRB) Stock Price - MarketBeat
Earnings call: Cellectar Biosciences delays NDA submission for iopofosine I 131 - Investing.com
Cellectar Biosciences Reports Q3 2024 Financial Results - TipRanks
Cellectar Biosciences Inc (CLRB) Quarterly 10-Q Report - Quartzy
Cellectar Biosciences Inc reports results for the quarter ended September 30Earnings Summary - XM
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update - GlobeNewswire
Cellectar Biosci stock hits 52-week low at $1.82 By Investing.com - Investing.com Canada
Cellectar Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cellectar corrects accounting firm consent in SEC filing - Investing.com
Cellectar corrects accounting firm consent in SEC filing By Investing.com - Investing.com Australia
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Short Interest Down 6.1% in October - MarketBeat
Cellectar Biosci stock hits 52-week low at $1.82 - Investing.com
Cellectar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Cellectar Reports Positive Phase 2 Results, Secures $19.4M in Warrant Exercises | CLRB Stock News - StockTitan
SEC Form 10-Q filed by Cellectar Biosciences Inc. - Quantisnow
Cellectar Biosciences (STU:NV4) Preferred Stock : €12.27 Mil (As of Sep. 2024) - GuruFocus.com
2.88%
2.65%
자본화:
|
볼륨(24시간):